Effectiveness of bismuth subgallate for preventing bleeding following adenotonsillectomy: A multicentre study.
Adenotonsillectomy
Bismuth subgallate
Postoperative bleeding
Journal
American journal of otolaryngology
ISSN: 1532-818X
Titre abrégé: Am J Otolaryngol
Pays: United States
ID NLM: 8000029
Informations de publication
Date de publication:
14 Dec 2023
14 Dec 2023
Historique:
received:
25
10
2023
accepted:
10
12
2023
medline:
24
12
2023
pubmed:
24
12
2023
entrez:
23
12
2023
Statut:
aheadofprint
Résumé
Tonsillectomy and adenotonsillectomy are surgical procedures routinely performed worldwide, with various complications, including postoperative bleeding (PTH). Among haemostatic agents, bismuth subgallate (BS) has been employed in the past decades, but its use is controversial in children. This retrospective, multicentre study aims to evaluate the effectiveness and safety of BS in preventing PTH following tonsillectomy and adenotonsillectomy. Two cohorts of children between 0 and 18 years of age were compared in two different hospitals. The first (active) group of patients included children who underwent tonsillectomy/adenotonsillectomy performed using BS added to gauze swabs, whereas this agent was not administered to the second (control) group. The following variables were analysed: age, gender, degree of tonsillar hyperplasia, length of hospital stay, acute complications (including bleeding and infection), further admissions to the Paediatric Emergency Department (PED), and further hospital admissions in the 30 days postoperatively. Four-thousand- seven hundred forty-four children were included in the study, 2598 in the active group and 2146 in the control group. The cases included in the active treatment group displayed a significantly reduced PTH prevalence, 1.4 versus 2.6 % (p < 0.05). No cases of neurological complications or aspiration pneumonia were detected. This study supports BS as a safe and reliable option for preventing severe PTH following tonsillectomy/adenotonsillectomy.
Sections du résumé
BACKGROUND
BACKGROUND
Tonsillectomy and adenotonsillectomy are surgical procedures routinely performed worldwide, with various complications, including postoperative bleeding (PTH). Among haemostatic agents, bismuth subgallate (BS) has been employed in the past decades, but its use is controversial in children.
OBJECTIVE
OBJECTIVE
This retrospective, multicentre study aims to evaluate the effectiveness and safety of BS in preventing PTH following tonsillectomy and adenotonsillectomy.
MATERIALS AND METHODS
METHODS
Two cohorts of children between 0 and 18 years of age were compared in two different hospitals. The first (active) group of patients included children who underwent tonsillectomy/adenotonsillectomy performed using BS added to gauze swabs, whereas this agent was not administered to the second (control) group. The following variables were analysed: age, gender, degree of tonsillar hyperplasia, length of hospital stay, acute complications (including bleeding and infection), further admissions to the Paediatric Emergency Department (PED), and further hospital admissions in the 30 days postoperatively.
RESULTS
RESULTS
Four-thousand- seven hundred forty-four children were included in the study, 2598 in the active group and 2146 in the control group. The cases included in the active treatment group displayed a significantly reduced PTH prevalence, 1.4 versus 2.6 % (p < 0.05). No cases of neurological complications or aspiration pneumonia were detected.
CONCLUSIONS
CONCLUSIONS
This study supports BS as a safe and reliable option for preventing severe PTH following tonsillectomy/adenotonsillectomy.
Identifiants
pubmed: 38141566
pii: S0196-0709(23)00408-8
doi: 10.1016/j.amjoto.2023.104194
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
104194Informations de copyright
Copyright © 2023 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest We declare that there are no prior publications or submission with any overlapping information, including studies and patients. We declare that the manuscript has not been and will not be submitted to any other journal while under consideration by American Journal of Otolaryngology--Head and Neck Medicine and Surgery. We declare that there is no competing interest in the submission we have made. We declare that none of the authors received any honorarium, grant, or other form of payment for this study. We declare that each author listed on the manuscript has seen and approved the submission of this version of the manuscript and takes full responsibility for the manuscript.